These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27995724)

  • 1. Canagliflozin versus placebo for post-bariatric surgery patients with persistent type II diabetes: A randomized controlled trial (CARAT).
    Kheniser K; Kashyap SR
    Diabetes Obes Metab; 2017 Apr; 19(4):609-610. PubMed ID: 27995724
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
    Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
    Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
    J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
    Nandula SR; Kundu N; Awal HB; Brichacek B; Fakhri M; Aimalla N; Elzarki A; Amdur RL; Sen S
    Cardiovasc Diabetol; 2021 Feb; 20(1):44. PubMed ID: 33581737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus.
    Wilding JP; Blonde L; Leiter LA; Cerdas S; Tong C; Yee J; Meininger G
    J Diabetes Complications; 2015 Apr; 29(3):438-44. PubMed ID: 25660137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
    Matthews DR; Zinman B; Tong C; Meininger G; Polidori D
    Diabet Med; 2016 Dec; 33(12):1744-1747. PubMed ID: 26600115
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
    Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POSTOPERATIVE INSULIN REQUIREMENTS IN BARIATRIC SURGERY.
    Diemer DM; Terry KL; Matthews M; Romich E; Saran H; Lansang MC
    Endocr Pract; 2017 Dec; 23(12):1369-1374. PubMed ID: 29019715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Matsutani D; Sakamoto M; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
    Cardiovasc Diabetol; 2018 May; 17(1):73. PubMed ID: 29788955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
    Inagaki N; Harashima SI; Kaku K; Kondo K; Maruyama N; Otsuka M; Kawaguchi Y; Iijima H
    Diabetes Obes Metab; 2018 Apr; 20(4):812-820. PubMed ID: 29110384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
    McCrimmon RJ; Catarig AM; Frias JP; Lausvig NL; le Roux CW; Thielke D; Lingvay I
    Diabetologia; 2020 Mar; 63(3):473-485. PubMed ID: 31897524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
    Inagaki N; Harashima S; Maruyama N; Kawaguchi Y; Goda M; Iijima H
    Cardiovasc Diabetol; 2016 Jun; 15():89. PubMed ID: 27316668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
    Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
    Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
    Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
    Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.
    Buysman EK; Chow W; Henk HJ; Rupnow MF
    BMC Endocr Disord; 2015 Nov; 15():67. PubMed ID: 26527413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.